February 25, 2021

Celiac Disease Foundation advocates urge congress To continue support of celiac disease research funding

LOS ANGELES – (February 18, 2021) – Celiac disease afflicts millions of Americans, most of whom are undiagnosed, and is second only to end-stage renal disease in perceived burden by patients and caregivers. Despite these appalling facts, the federal government has never been a major funder of celiac disease research. As a direct consequence, celiac disease is the most prevalent genetic autoimmune disease with no FDA-approved treatments.

Celiac Disease Foundation Advocates Urge Congress To Continue Support of Celiac Disease Research Funding

February 24, 2021

Walgreens to make Pixel by Labcorp™ COVID-19 PCR Test Home Collection Kit available over-the-counter at stores nationwide

DEERFIELD, Ill. & BURLINGTON, N.C., February 24, 2021 - As part of Walgreens ongoing efforts to increase access to COVID-19 testing in communities across the U.S., the company announced today it has entered into an agreement with Labcorp™ to sell Pixel by Labcorp COVID-19 PCR Test Home Collection Kits over-the-counter in up to 6,000 Walgreens stores nationwide beginning in spring of this year. Walgreens is making significant strides to increase on-site testing capacity at more than 5,000 Walgreens pharmacy locations by April 1, with more than half of sites located in socially vulnerable areas.
February 22, 2021

Labcorp and EmblemHealth announce strategic collaboration to serve over 3 million members In New York communities

BURLINGTON, N.C., February 22, 2021— Labcorp (NYSE: LH), a leading global life sciences company, and EmblemHealth, one of the nation’s largest nonprofit health insurers, have entered into a strategic collaboration to provide laboratory testing services to the more than 3 million participants enrolled in EmblemHealth plans in New York and New Jersey. The preferred provider agreement allows EmblemHealth to offer its members best-in-class service and easier access to high-quality lab testing.
February 19, 2021

Labcorp and Circuit Clinical collaborate to bring clinical trials directly to patients and increase access to underrepresented populations

Burlington, NC and Buffalo, NY – February 19, 2021 – Labcorp, (NYSE: LH), a leading global life sciences company, and Circuit Clinical®, a network of physicians and clinical research professionals devoted to and passionate about bringing clinical research to everyone, today announced a collaboration to bring clinical trials directly to patients in the places, and with the people, their communities trust most to deliver healthcare services.
February 19, 2021

Pacific Biosciences Sequel II Systems deployed to scale-up global viral surveillance initiatives focused on COVID-19

MENLO PARK, Calif., Feb. 18, 2021 (GLOBE NEWSWIRE) --Pacific Biosciences of California, Inc. (Nasdaq: PACB), a leading provider of high-quality, long-read sequencing platforms, today announced that Labcorp (NYSE: LH), a leading global life sciences company, has increased its commitment to highly accurate HiFi sequencing with the addition of new PacBio® Sequel® II Systems. The new systems will expand Labcorp’s capacity to generate thousands of more complete coronavirus genomes from patient samples each week. These data are being used by the United States (U.S.) Centers for Disease Control and Prevention (CDC) to track the spread of existing SARS-CoV-2 variants and detect the emergence of new variants circulating in different geographic regions. Most recently, Labcorp and the CDC utilized PacBio HiFi sequencing data to identify the first known cases of infection from the B.1.351 variant in both South Carolina1 and Virginia2.

Labcorp's perspective: Responding to SARS-CoV-2 and the next pandemic